Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
6.2 USD -29.34% Intraday chart for Avenue Therapeutics, Inc. -36.41% -48.65%
03-18 Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-22 Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy CI

Evolution of the average Target Price on Avenue Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b5814adb6cf1f9e7711fb3.VebBAb0PHL0Zz4Mx5P4gk5UZBdOsbABtomK4xtdhmWQ.IrKict5aU4lBtcZrjZJ1-MxKX73JXlQexgPMo7wx9D1loIhskDhu9m2Qzg~fac67ca281e8118640f2438d855d4302

Analyst Recommendations on Avenue Therapeutics, Inc.

Maxim Starts Coverage on Avenue Therapeutics with Buy Rating, $0.75 Price Target MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist DJ
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High MT
US Futures Lower as Mortgage Rates Climb to 16-Year High MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.2 USD
Average target price
1,228 USD
Spread / Average Target
+19,708.52%
High Price Target
2,400 USD
Spread / Highest target
+38,609.77%
Low Price Target
56.25 USD
Spread / Lowest Target
+807.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Avenue Therapeutics, Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. Consensus Avenue Therapeutics, Inc.